ClinicalTrials.gg
CompletedNCT00517829Updated Nov 28, 2016Results posted

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

A Phase 2 interventional study of Docetaxel and cetuximab in Gastric Cancer Adenocarcinoma Metastatic, sponsored by US Oncology Research. Completed at 47 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing cetuximab in Stomach Neoplasms — none open to participants now, none under way, none of them phase 3. Cetuximab · Stomach Neoplasms.

Enrollment
2nd of 17
150 · median 41
Started
2007
with 2 others
Phase 2
12 of 17
none open now
Registered
10th of 17
by date

Among the 17 studies testing cetuximab in Stomach Neoplasms, this one is the 2nd largest by enrollment, is one of 3 that started in 2007, is one of 12 in phase 2, and was the 10th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

None of the 17 studies testing cetuximab in Stomach Neoplasms is open now. The open studies under Stomach Neoplasms, anywhere →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing cetuximab in Stomach Neoplasms as a file.
02

Study summary

The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.

Read the detailed description

This is a Phase II, open- label, randomized, noncomparative study. Patients will be stratified at randomization by ECOG PS. There is no intent to have equal numbers of patients for each PS (ie, 0, 1, and 2), but rather stratification will be conducted to ensure that the 2 treatment arms are well-balanced for ECOG PS.

Patients will be randomly assigned to either Arm 1 - Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour, followed by Eloxatin 130 mg/m2 IV over 2 hours or Arm 2 - Taxotere 60 mg/m2 as an IV infusion over 1 ho ur, followed by Eloxatin 130mg/m2 IV over 2 hours, followed by ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes. Taxotere and Eloxatin will be given on Day 1 of each 21-day cycle; ERBITUX is given on Days 1, 8, and 15 of each cycle.

Treatment will continue until disease progression or intolerable toxicity. Patients who achieve a CR will receive an additional 2 cycles of treatment. Patients will be limited to 24 months of participation, counted from the date of the first dose of study drug.

03

Conditions studied

  • Gastric Cancer Adenocarcinoma Metastatic

Browse trials for

Keywords

  • metastatic gastric or adenocarcinoma of the GE junction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has confirmed Stage IV adenocarcinoma of the GEJ/stomach

Note: radiation plus treatment with 5-FU and leucovorin is permitted, but not required.

  • Patients must have
  • Patient has an (ECOG) Performance Status (PS) 0-2
  • Patient is greater than 18 years of age
  • If present, any pre-existing (current) peripheral neuropathy must be ≤ Grade 1
  • Patient's laboratory values must fall within the limits set forth in section 4.2 of the protocol
  • Patient has a negative serum pregnancy test within 7 days prior to registration (female patients of )
  • If fertile, patient (male or female) has agreed to use an acceptable method of to avoid pregnancy for the duration of the study and for a 2 month period thereafter
  • Patient (or guardian) has signed a Patient Form
  • Patient (or guardian) has signed a Patient Authorization Form

Exclusion criteria

Exclusion Criteria:

  • Patient has any disease other than that defined in section 4.2 (criterion #1)
  • Patient has had prior treatment that included anything other than radiation plus treatment with 5-FU and leucovorin. Prior treatment must have been completed > 6 months prior to registration in current study. No other prior regimens are allowed.

Note: Adjuvant radiation plus treatment with 5-FU and leucovorin is permitted, but not required.

  • If present, any peripheral neuropathy is > Grade 1
  • Patient has a known to Taxotere (or any drug formulated with Polysorbate-80), or Eloxatin
  • Has had a prior severe infusion reaction (Grade 4) to a monoclonal antibody
  • Has received prior therapy, at any time, which specifically and directly targets the EGFR pathway
  • Patient is receiving concurrent immunotherapy or any other concurrent treatment for their cancer
  • Has had prior stem cell or bone marrow transplant or any organ transplant with the exception of corneal transplant or cadaver bone graft
  • Has a significant history of uncontrolled cardiac disease; ie, uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, or cardiomyopathy with decreased (LVEF\<50%)
  • Has evidence of CNS involvement (CNS imaging is not required for study enrollment unless clinically suspected CNS disease is present.)
  • Patient has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
  • Patient is known to be positive or have a history of or C
  • Patient has a history of other within the last 5 years (except for squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix , or superficial transitional cell carcinoma of the bladder), which could affect the diagnosis or assessment of current condition.
  • Patient is a pregnant or lactating woman
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Active comparator
    1- Docetaxel plus Oxaliplatin

    Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours

    Drug: Docetaxel · Drug: oxaliplatin

  • Active comparator
    2- Docetaxel plus oxaliplatin plus cetuximab

    Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.

    Drug: Docetaxel · Drug: cetuximab · Drug: oxaliplatin

Interventions

  • Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour

    Also known as: Taxotere (docetaxel)

  • ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.

    Also known as: ERBITUX (cetuximab)

  • Eloxatin 130 mg/m2 IV over 2 hours

    Also known as: Eloxatin (oxaliplatin)

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Treatment will continue until disease progression or intolerable toxicity, up to 2 years

Secondary outcomes

  1. Overall Survival

    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: Treatment will continue until disease progression or intolerable toxicity

  2. Objective Response Rate (ORR)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.

    Time frame: Treatment will continue until disease progression or intolerable toxicity.

  3. Time to Response

    For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.

    Time frame: Treatment will continue until disease progression or intolerable toxicity

  4. Duration of Response

    The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

    Time frame: Treatment will continue until disease progression or intolerable toxicity

07

Results

Posted Feb 11, 2016

Participant flow

Participant flow — Overall Study
MilestoneDOCOXDOCOX+Cebuximab
Started7575
Completed00
Not completed7575
Withdrew: Adverse event2234
Withdrew: Disease progression3932
Withdrew: Patient request65
Withdrew: Investigator request53
Withdrew: Other31

Outcome measures

PrimaryProgression-free Survival

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Treatment will continue until disease progression or intolerable toxicity, up to 2 years
Reported as:
Median · months
Progression-free Survival
monthsDOCOXDOCOX+Cebuximab
Progression-free Survival4.7 (3.0 to 5.6)5.1 (4.3 to 5.9)
SecondaryOverall Survival

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
Treatment will continue until disease progression or intolerable toxicity
Reported as:
Median · months
Overall Survival
monthsDOCOXDOCOX+Cebuximab
Overall Survival8.5 (7.1 to 12.0)9.4 (6.7 to 10.1)
SecondaryObjective Response Rate (ORR)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.

Time frame:
Treatment will continue until disease progression or intolerable toxicity.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsDOCOXDOCOX+Cebuximab
Objective Response Rate (ORR)26.5 (16.5 to 38.6)38.0 (26.8 to 50.3)
SecondaryTime to Response

For patients who achieve a major objective response (CR or PR) the time to response will be assessed as the date of registration to the date of response.

Time frame:
Treatment will continue until disease progression or intolerable toxicity
Reported as:
Median · months
Time to Response
monthsDOCOXDOCOX+Cebuximab
Time to Response1.3 (1.1 to 5.2)1.4 (1.1 to 4.0)
SecondaryDuration of Response

The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented.

Time frame:
Treatment will continue until disease progression or intolerable toxicity
Reported as:
Median · months
Duration of Response
monthsDOCOXDOCOX+Cebuximab
Duration of Response7.3 (1.5 to 23.7)5.6 (2.3 to 13.2)

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DOCOX—20/68 (29.4%)65/68 (95.6%)
DOCOX+Cebuximab—26/72 (36.1%)67/72 (93.1%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventDOCOXDOCOX+Cebuximab
FEBRILE NEUTROPENIAInfections and infestations7/6813/72
DIARRHEAGastrointestinal disorders5/684/72
DEHYDRATIONGastrointestinal disorders4/683/72
ANEMIABlood and lymphatic system disorders3/681/72
ABDOMINAL PAINGastrointestinal disorders2/680/72
GASTROINTESTINAL BLEEDINGGastrointestinal disorders2/680/72
INFECTIONInfections and infestations2/681/72
ALLERGIC REACTIONImmune system disorders1/682/72
COLITISGastrointestinal disorders1/682/72
NEUROPATHYNervous system disorders0/682/72
Most frequent other events
Showing 10 of 38
Most frequent other events
EventDOCOXDOCOX+Cebuximab
NEUTROPENIABlood and lymphatic system disorders45/6841/72
FATIGUEGeneral disorders33/6836/72
DIARRHEAGastrointestinal disorders26/6834/72
RASH ACNEFORMSkin and subcutaneous tissue disorders0/6832/72
NAUSEAGastrointestinal disorders26/6827/72
ALOPECIASkin and subcutaneous tissue disorders22/6817/72
ANEMIABlood and lymphatic system disorders19/6819/72
NEUROPATHYNervous system disorders17/689/72
RASHSkin and subcutaneous tissue disorders2/6817/72
NEUROPATHY PERIPHERALNervous system disorders12/6816/72

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)DOCOXDOCOX+CebuximabTotal
Mean60.5 ± 10.961.5 ± 11.561.0 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)DOCOXDOCOX+CebuximabTotal
Female161531
Male5960119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)DOCOXDOCOX+CebuximabTotal
Caucasian6256118
Black5712
Hispanic5914
Asian314
Hawaiian011
Other011
Region of Enrollment
Region of Enrollment(participants)DOCOXDOCOX+CebuximabTotal
United States7575150
08

Study locations

47 sites
  • Birmingham Hematology and Oncology
    Birmingham, Alabama 35205, United States
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Rocky Mountain Cancer Center - Midtown
    Denver, Colorado 80218, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Hematology Oncology Associates of Illinois
    Chicago, Illinois 60611, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Hope Center
    Terre Haute, Indiana 47802, United States
  • Kansas City Cancer Centers - Southwest
    Overland Park, Kansas 66210, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • New York Oncology Hematology, P.C.
    Hudson, New York 12534, United States
  • Interlakes Oncology Hematology, PC
    Rochester, New York 14623, United States
  • Cancer Centers of North Carolina
    Raleigh, North Carolina 27607, United States
  • Mahoning Valley Hematology Oncology Associates
    Boardman, Ohio 44514, United States
  • Greater Dayton Cancer Center
    Kettering, Ohio 45409, United States
  • Medical Oncology Associates
    Kingston, Pennsylvania 18704, United States
  • Texas Oncology, P.A. Amarillo
    Amarillo, Texas 79106, United States
  • Texas Cancer Center
    Arlington, Texas 76014, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702, United States
  • Texas Oncology, P.A. - Bedford
    Bedford, Texas 76022, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75231, United States
  • Methodist Charlton Cancer Ctr.
    Dallas, Texas 75237, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Cancer Center
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Ctr
    El Paso, Texas 79915, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • Texas Oncology, P.A.
    Garland, Texas 75042, United States
  • Lake Vista Cancer Center
    Lewisville, Texas 75067, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • Texas Cancer Center of Mesquite
    Mesquite, Texas 75150, United States
  • Allison Cancer Center
    Midland, Texas 79701, United States
  • Texas Oncology - Odessa
    Odessa, Texas 79761, United States
  • Paris Regional Cancer Center
    Paris, Texas 75460, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texas Oncology Cancer and Research
    Waco, Texas 76712, United States
  • Fairfax Northern VA Hem-Onc PC
    Arlington, Virginia 22205, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Onc and Hem Associates of SW VA, Inc.
    Salem, Virginia 24153, United States
  • Puget Sound Cancer Center - Edmonds
    Edmonds, Washington 98026, United States
  • Columbia Basin Hematology & Oncology
    Kennewicke, Washington 99336, United States
  • Puget Sound Cancer Center - Seattle
    Seattle, Washington 98133, United States
  • Cancer Care Northwest - South
    Spokane, Washington 99202, United States
  • Northwest Cancer Specialist - Vancouver
    Vancouver, Washington 98684, United States
09

References and documents

Publications

  • Richards D, Kocs DM, Spira AI, David McCollum A, Diab S, Hecker LI, Cohn A, Zhan F, Asmar L. Results of docetaxel plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. Eur J Cancer. 2013 Sep;49(13):2823-31. doi: 10.1016/j.ejca.2013.04.022. Epub 2013 Jun 5. PubMed 23747051 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2007
First posted
Aug 17, 2007
Start
Jul 2007
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Feb 11, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00517829
Responsible party
Sponsor
First posted
Aug 17, 2007
Start date
Jul 2007
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Feb 11, 2016
Last update
Nov 28, 2016

Study contacts

Donald A Richards, MD
principal investigator · US Oncology Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion